3579 |
Memorial Lecture 2018: 40 Years of PCI - Where Next? |
Bernhard Meier |
Apr. 28. 18 |
3578 |
Enhancing CV Outcomes: LDL-C and Beyond |
Cheol Woong Yu |
Apr. 28. 18 |
3577 |
Drug-Eluting Balloon – Leaving Nothing Behind: Attractive Treatment with ¡°Procedure Optimization¡± |
Joo Myung Lee |
Apr. 28. 18 |
3576 |
Clinical Experience of 3-Month Dual Antiplatelet Therapy in Coroflex ISAR Stent |
Myeong-Ho Yoon |
Apr. 28. 18 |
3575 |
The Future Pipelines and Perspectives on Next Bioresorbable Scaffolds |
Chuck Simonton |
Apr. 28. 18 |
3574 |
Polymer-Free Sirolimus-Eluting Stents in a Large-Scale All-Comers Population |
Soon Jun Hong |
Apr. 28. 18 |
3573 |
Drug Eluting Bioresorbable Mg Scaffold |
Michael Haude |
Apr. 28. 18 |
3572 |
Why BVS Failed |
Stephen G. Ellis |
Apr. 28. 18 |
3571 |
Updated Meta-Analysis of Bioresorbable Scaffolds: Sum Up Many, Many Meta for BRS |
Tullio Palmerini |
Apr. 28. 18 |
3570 |
The Efficacy and Safety of Ticagrelor Versus Clopidogrel in Acute Myocardial Infarction in Taiwan |
Yi-Heng Li |
Apr. 28. 18 |